Analysis of repeated low-dose challengestudies

Statistics in Medicine

Volumn 34, Issue 12, 2015, Pages 1981-1992

  Nolen, Tracy L ^a   Hudgens, Michael G ^b   Senb, Pranab K ^b,c   Koch, Gary G ^b  

^a RTI INTERNATIONAL   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c The University of North Carolina at Chapel Hill   (United States)

Author keywords

HIV; Macaque; Permutation test; Pre clinical studies; Randomization inference; Vaccine

Indexed keywords

ANALYTIC METHOD; ARTICLE; CALCULATION; CONTROLLED STUDY; FISHER EXACT TEST; LOG RANK TEST; LOW DRUG DOSE; MATHEMATICAL COMPUTING; MATHEMATICAL MODEL; RANDOMIZATION; REPEATED DRUG DOSE; SIMULATION; ANIMAL; COMPUTER SIMULATION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; HUMAN; IMMUNOLOGY; MONTE CARLO METHOD; PRECLINICAL STUDY; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

SIMIAN IMMUNODEFICIENCY VIRUS VACCINE;

ANIMALS; COMPUTER SIMULATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HUMANS; MACACA MULATTA; MONTE CARLO METHOD; SAIDS VACCINES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84929288644     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.6462     Document Type: Article

References (34)

1. Koff WC, Johnson PR, Watkins DI, Burton DR, Lifson JD, Hasenkrug KJ, McDermott AB, Schultz A, Zamb TJ, Boyle R, Desrosiers RC. HIV vaccine design: insights from live attenuated SIV vaccines. Nature Immunology 2006; 7(1):19-23.
2. Shedlock DJ, Silvestri G, Weiner DB. Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials. Nature Reviews Immunology 2009; 9(10):717-728.
3. McDermott AB, Mitchen J, Piaskowski S, DeSouza I, Yant LJ, Stephany J, Furlott J, Watkins DI. Repeated low-dose mucosal simian immunodeficiency virus SIVmac239 challenge results in the same viral and immunological kinetics as high-dose challenge: a model for the evaluation of vaccine efficacy in nonhuman primates. Journal of Virology 2004; 78(6):3140-3144.
4. Staprans SI, Feinberg MB, Shiver JW, Casimiro DR. Role of nonhuman primates in the evaluation of candidate AIDS vaccines: an industry perspective. Current Opinion in HIV and AIDS 2010; 5(5):377-385.
5. Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, Wabwire-Mangen F, Lutalo T, Li X, vanCott T, Quinn TC, Rakai Project Team . Probability of HIV-1 transmission per coital act in monogamous, heterosexual HIV-1-discordant couples in Rakai, Uganda. Lancet 2001; 357:1149-1153.
6. Boily MC, Baggaley RF, Wang L, Masse B, White RG, Hayes RJ, Alary M. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infectious Diseases 2009; 9(2):118-129.
7. WHO/UNAIDS/IAVI International Expert Group. Executive summary and recommendations from the WHO/UNAIDS/IAVI expert group consultation on 'Phase IIB-TOC trials as a novel strategy for evaluation of preventive HIV vaccines', 31 January-2 February 2006, IAVI, New York, USA. AIDS 2007; 21:539-546.
8. Regoes RR, Longini IM, Feinberg MB, Staprans SI. Preclinical assessment of HIV vaccines and microbicides by repeated low-dose virus challenges. PLoS Medicine 2005; 2(8):0798-0807.
9. Hessell AJ, Poignard P, Hunter M, Hangartner L, Tehrani DM, Bleeker WK, Parren PW, Marx PA, Burton DR. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nature Medicine 2009; 15:951-954.
10. Hudgens MG, Gilbert PB, Mascola J, Wu CD, Barouch D, Self SG. Power to detect the effects of HIV vaccination in repeated low-dose challenge experiments. Journal of Infectious Diseases 2009; 200:609-613.
11. Hudgens MG, Gilbert PB. Assessing vaccine effects in repeated low-dose challenge experiments. Biometrics 2009; 65(4):1223-1232.
12. Garcia-Lerma JG, Otten RA, Qari SH, Jackson E, Cong ME, Masciotra S, Luo W, Kim C, Adams DR, Monsour M, Lipscomb J, Johnson JA, Delinsky D, Schinazi RF, Janssen R, Folks TM, Heneine W. Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Medicine 2008; 5:0291-0299.
13. Parikh UM, Dobard C, Sharma S, Cong M, Jia H, Martin A, Pau CP, Hanson DL, Guenthner P, Smith J, Kersh E, Garcia-Lerma JG, Novembre FJ, Otten R, Folks T, Heneine W. Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. Journal of Virology 2009; 83(20):10358-10365.
14. Reynolds MR, Weiler AM, Piaskowski SM, Kolar HL, Hessell AJ, Weiker M, Weisgrau KL, León EJ, Rogers WE, Makowsky R, McDermott AB, Boyle R, Wilson NA, Allison DB, Burton DR, Koff WC, Watkins DI. Macaques vaccinated with simian immunodeficiency virus SIVmac239Δnef delay acquisition and control replication after repeated low-dose heterologous SIV challenge. Journal of Virology 2010; 84(18):9190-9199.
15. Koch GG, Gillings DB, Stokes ME. Biostatistical implications of design, sampling, and measurement to health science data analysis. Annual Review of Public Health 1980; 1:163-225.
16. Rubin DB. Practical implications of modes of statistical inference for causal effects and the critical role of the assignment mechanism. Biometrics 1991; 47:1213-1234.
17. Rosenbaum PR. Observational Studies. Springer-Verlag: New York, 2002.
18. Rubin DB. Causal inference using potential outcomes: design, modeling, decisions. Journal of the American Statistical Association 2005; 100:322-331.
19. Agresti A. Categorical Data Analysis, Second Edition. John Wiley and Sons: New York, 1990.
20. Stokes ME, Davis CS, Koch GG. Categorical Data Analysis Using the SAS System, Second Edition. SAS Institute Inc.: Cary, NC, 2000.
21. SAS Institute Inc.. SAS/STAT 9.2 UserŠs Guide, Second Edition. SAS Institute Inc.: Cary, NC, 2009.
22. Ellenberger D, Otten RA, Li B, Rodriguez V, Sariol CA, Martinez M, Monsour M, Wyatt L, Hudgens MG, Kraiselburd E, Moss B, Robinson H, Folks T, Butera S. HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges. Virology 2006; 352:216-225.
23. Cox DR. Regression models and life-tables. Journal of the Royal Statistical Society. Series B (Methodological) 1972; 34(2):187-220.
24. Brown CC. On the use of indicator variables for studying the time-dependence of parameters in a response-time model. Biometrics 1975; 31(4):863-872.
25. Allison PD. Discrete-time methods for the analysis of event histories. Sociological Methodology 1982; 13(1):61-98.
26. Singer JD, Willett JB. Its about time: using discrete-time survival analysis to study duration and the timing of events. Journal of Educational and Behavioral Statistics 1993; 18(2):155-195.
27. R Core Team. R: a language and environment for statistical computing. R Foundation for Statistical Computing: Vienna, Austria, 2013. URL http://www.R-project.org/.
28. Therneau TM. A package for survival analysis in S, 2013. URL http://CRAN.R-project.org/package=survival, r package version 2.37-4.
29. Cytel Software Corporation. StatXact 8.0 for Windows User Manual. Cytel Software Corporation: Cambridge, MA, 2007.
30. Callaert H. Comparing statistical software packages: the case of the logrank test in StatXact. The American Statistician 2003; 57(3):214-217.
31. Hothorn T, Hornik K, van de Wiel MA, Zeileis A. Implementing a class of permutation tests: the coin package. Journal of Statistical Software 2008; 28(8):1-23. URL http://www.jstatsoft.org/v28/i08/.
32. Hothorn T, Lausen B. On the exact distribution of maximally selected rank statistics. Computational Statistics & Data Analysis 2003; 43(2):121-137.
33. Cox DR. Analysis of Binary Data. Chapman and Hall: London, 1970.
34. Longini IM, Halloran ME. A frailty mixture model for estimating vaccine efficacy. Applied Statistics 1996; 45:165-173.